2seventy bio Q4 EPS $(1.11) Misses $(0.99) Estimate, Sales $10.68M Miss $14.71M Estimate
Portfolio Pulse from Benzinga Newsdesk
2seventy bio (NASDAQ:TSVT) reported Q4 earnings with a loss of $(1.11) per share, missing the $(0.99) estimate, and sales of $10.68M, missing the $14.71M estimate. This represents an 85% decrease in EPS and an 80.98% decrease in sales from the same period last year.
March 05, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
2seventy bio reported a significant miss in both EPS and sales for Q4, with an 85% decrease in EPS and an 80.98% decrease in sales year-over-year.
The significant miss in both EPS and sales compared to analyst estimates and the substantial year-over-year decrease in these metrics are likely to negatively impact investor sentiment and the stock price of 2seventy bio in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100